FARN — Faron Pharmaceuticals Oy Share News
0.000.00%
Last trade - 00:00Appointment of CFO
Faron’s Financial Calendar for 2026
INSIDE INFORMATION: FARON INTENDS TO ISSUE SECOND TRANCHE OF BONDS WITH AN AGGREGATED PRINCIPAL AMOUNT OF EUR 10 MILLION UNDER ITS CONVERTIBLE BOND ARRANGEMENT
AIM - AIM Notice - 29/10/2025
Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds
HOLDING(S) IN COMPANY
Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients
AIM - AIM Notice - 10/10/2025
AIM - AIM Notice - 06/10/2025
AIM - AIM Notice - 04/06/2025
Brief: Faron Enters Into Up To EUR 35 Million Convertible Bond Arrangement
Brief: Faron Pharmaceuticals Says FDA Grants Orphan Drug Designation
Faron Pharma. Oy - FDA Grants Orphan Drug Designation
Faron Pharma. Oy - Notice of Annual General Meeting
Advisory: Dated alert on Faron Pharmaceuticals' appointment of CEO, CFO withdrawn
Faron Pharma. Oy - Positive EMA Opinion on Orphan Drug Designation
Faron Pharma. Oy - Annual Report 2024 published
Faron Pharma. Oy - Financial Statement 1 January to 31 December 2024
Faron Pharma. Oy - Notice of Financial Statement and Annual Report